Movement Alert|Duality Biotherapeutics-B Falls 5.59% in Regular Trading, Continued Correction From Highs Despite Recent Positive Catalysts

Market Focus
06/01

On June 1, Duality Biotherapeutics-B fell 5.59% in regular trading, trading at 212.6 HKD/share, with trading volume of HKD 155 million.

The stock has now retreated approximately 60% from its September high. Despite multiple recent positive developments — including a global Phase III first patient dosing for DB-1311/BNT324 in partnership with BioNTech, share buybacks totaling over HKD 26 million across several sessions in late May, and institutional accumulation by LAV Asset Management increasing its stake to 13.00% — selling pressure has persisted amid broader sector weakness.

Within the Biotechnology sector, performance was mixed. Among individual stocks, AKESO rose 2.46%, 3SBIO gained 0.65%, while INNOVENT BIO fell 2.58%, BEIGENE declined 2.55%, and SKB BIO dropped 3.33%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10